We have collected information about Drug Delivery Trends In Clinical Trials And Translational Medicine for you. Follow the links to find out details on Drug Delivery Trends In Clinical Trials And Translational Medicine.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4867146/
However, when we summarized trials by drug delivery, biological platforms, and disease categories, less than 10% of these trials included pharmacokinetic evaluation in elderly subjects greater than 65 years of age, and less than 4% included pharmacokinetic evaluation in children …Author: Jenny Y. Chien, Rodney J.Y. Ho
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826476/
Approximately half (47,467) are related to the three categories within the scope of the free online resource “Drug Delivery Trends in Clinical Trials and Translational Medicine,” which are (1) drug delivery technology and systems, (2) biological molecule platforms, and (3) pharmacokinetic and pharmacodynamic interactions.Author: Rodney J.Y. Ho, Rodney J.Y. Ho, Jenny Y. Chien
https://www.sciencedirect.com/science/article/pii/S0022354915314738
There are 94,709 clinical trials across 179 countries. Approximately half (47,467) are related to the three categories within the scope of the free online resource “Drug Delivery Trends in Clinical Trials and Translational Medicine,” which are (1) drug delivery technology and systems, (2) …Author: Rodney J.Y. Ho, Rodney J.Y. Ho, Jenny Y. Chien
https://onlinelibrary.wiley.com/doi/full/10.1002/jps.22243
Drug delivery trends in clinical trials and translational medicine: Challenges and opportunities in the delivery of nucleic acid‐based therapeutics Long Xu Department of Pharmaceutical Sciences, University of Colorado, 12700 East Nineteenth Avenue, Aurora, Colorado 80045Author: Long Xu, Thomas J. Anchordoquy
https://www.sciencedirect.com/science/article/pii/S0022354916329756
With the up-to-date clinical trial data as a starting point, we develop our commentaries to inform scientists in the pharmaceutical science community about the translational trends in the state-of-the-art drug delivery technologies and innovative formulation strategies.Author: Rodney J.Y. Ho, Jenny Y. Chien
https://onlinelibrary.wiley.com/doi/pdf/10.1002/jps.22243
CLINICAL TRIALS AND TRANSLATIONAL MEDICINE COMMENTARY Drug Delivery Trends in Clinical Trials and Translational Medicine: Challenges and Opportunities in the Delivery of Nucleic Acid-Based Therapeutics LONG XU, THOMAS ANCHORDOQUY Department of Pharmaceutical Sciences, University of Colorado, 12700 East Nineteenth Avenue, Aurora, Colorado 80045Author: Long Xu, Thomas J. Anchordoquy
https://www.ncbi.nlm.nih.gov/pubmed/19117050
Drug delivery trends in clinical trials and translational medicine: Updated analysis of ClinicalTrials.gov database. Ho RJ(1), Chien JY. Author information: (1)Department of Pharmaceutics, University of Washington, and Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. [email protected]: Rodney J.Y. Ho, Jenny Y. Chien
https://www.sciencedirect.com/science/article/abs/pii/S0022354916329756
In essence, integration of drug delivery and targeting to reduce exposure in off-target tissues in the preclinical and clinical program may hold the key to increasing the odds of success in drug development. In this update, we briefly review data on clinical trials pertinent to drug delivery in the current regulatory environment.Author: Rodney J.Y. Ho, Jenny Y. Chien
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3303188/
Drug Delivery Trends in Clinical Trails and Translational Medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics Long Xu and Thomas J. Anchordoquy University of Colorado School of Pharmacy, Aurora, CO 80045Author: Long Xu, Thomas J. Anchordoquy
https://www.sciencedirect.com/science/article/pii/S0022354915323297
Recent studies have utilized human transferrin (approximately 80 kDa with significant secondary structure) as a targeting ligand for a cyclodextrin-based siRNA delivery system. 103 Although the ability of this system to efficiently deliver siRNA is currently being tested in clinical trials by Calando Pharmaceuticals, 107 it is unlikely that a protein-based ligand like transferrin would ultimately be used in a commercial drug delivery product. Furthermore, many academic studies …Author: Long Xu, Thomas J. Anchordoquy
Searching for Drug Delivery Trends In Clinical Trials And Translational Medicine?
You can just click the links above. The data is collected for you.
